Evidence map›Paper›PMID 38310467›Full record

ArticleCurrent HIV research2024

Mortality Risk Factors Among People Living with HIV Receiving Second-line Antiretroviral Therapy in Rural China.

Qiujia Kang, Wanqi Pan, Yanmin Ma, Dongli Wang, Huangchao Jia, Huijun Guo, Feng Sang, Liran Xu, Qianlei Xu, Yantao Jin

Abstract read
PubMed Publisher
In one paragraph

Article in Current HIV research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Qiujia KangThe First Clinical Medical School, Henan University of Chinese Medicine, Zhengzhou, 45000, China.
Wanqi PanThe First Clinical Medical School, Henan University of Chinese Medicine, Zhengzhou, 45000, China.
Yanmin MaCenter for AIDS/STD Control and Prevention, Center for Disease Control and Prevention of Henan Province, Zhengzhou, 45000, China.
Dongli WangThe First Clinical Medical School, Henan University of Chinese Medicine, Zhengzhou, 45000, China.
Huangchao JiaThe First Clinical Medical School, Henan University of Chinese Medicine, Zhengzhou, 45000, China.
Huijun GuoDepartment of Acquired Immune Deficiency Syndrome Treatment and Research Center, First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 45000, China.
Feng SangHenan Key Laboratory of Viral Diseases Prevention and Treatment of Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou, 45000, China.
Liran XuDepartment of Acquired Immune Deficiency Syndrome Treatment and Research Center, First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 45000, China.
Qianlei XuThe First Clinical Medical School, Henan University of Chinese Medicine, Zhengzhou, 45000, China.
Yantao JinDepartment of Acquired Immune Deficiency Syndrome Treatment and Research Center, First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 45000, China.
First Affiliated Hospital of Henan University · CNHenan Provincial Center for Disease Control and Prevention · CN

Funding

National Natural Science Foundation of China (NSFC) 81803953,81803953
6 · The paper itself

Abstract

backgroundSecond-line antiretroviral therapy (ART) was introduced in Henan Province in 2009. The number of people living with human immunodeficiency virus (HIV) starting this therapy is increasing.

objectiveThis study aimed to investigate the survival and factors affecting mortality among this group.

methodsWe conducted a retrospective cohort study of people living with HIV (PLHIV) who switched to second-line ART between May 1, 2010, and May 1, 2016, using the Kaplan-Meier method and Cox proportional hazards models.

resultsWe followed 3,331 PLHIV for 26,988 person-years, of whom 508 (15.3%) died. The mortality rate was 1.88/100 person-years. After adjusting for confounding factors, we found being a woman (hazard ratio (HR), 0.66; 95% confidence interval (CI) 0.55-0.79), > 50 years old (HR, 2.69; 95% CI, 2.03-3.56), single/widowed (HR, 1.26; 95% CI, 1.04-1.52), having > 6 years of education (HR, 0.78; 95% CI, 0.65-0.94), Chinese medicine (HR, 0.75; 95% CI, 0.52-0.96), liver injury (HR, 1.58; 95% CI, 1.19-2.10), and CD4+ T cell count <200 cells/μl (HR, 1.94; 95% CI, 1.47-2.55), or 200-350 cells/μl (HR, 1.37; 95% CI, 1.03-1.82) were associated with mortality risk.

conclusionsWe found lower mortality among PLHIV who switched to second-line ART than most previous studies. The limitations of a retrospective cohort may, therefore, have biased the data, and prospective studies are needed to confirm the results. Moreover, Chinese medicine combined with second-line ART shows potential as a treatment for HIV.

Indexed as

HIV InfectionsRural PopulationAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountChinaFemaleHumansMaleMiddle AgedProportional Hazards ModelsRetrospective StudiesRisk FactorsYoung AdultAnti-HIV Agentsacquired immune deficiency syndromeHuman immunodeficiency virusmortalityPLHIVsecond-line antiretroviral therapysurvival.

Identifiers

PMID38310467
OpenAlexW4391522205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.